Major depressive disorder and nutritional medicine: A review of monotherapies and adjuvant treatments

Nutrition Reviews

Volumn 67, Issue 3, 2009, Pages 125-131

  Sarris, Jerome ^a   Schoendorfer, Niikee ^a   Kavanagh, David J ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Depression; Folic acid; L tryptophan; Nutrition; Omega 3; SAMe

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; DOCOSAHEXAENOIC ACID; FLUOXETINE; FOLIC ACID; ICOSAPENTAENOIC ACID; IMIPRAMINE; INOSITOL; OLIVE OIL; OMEGA 3 FATTY ACID; PLACEBO; S ADENOSYLMETHIONINE; SEROTONIN UPTAKE INHIBITOR; TRANYLCYPROMINE; TRYPTOPHAN; VENLAFAXINE; AMINO ACID;

ADJUVANT THERAPY; BIPOLAR DEPRESSION; BIPOLAR DISORDER; DEPRESSION; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG MANUFACTURE; DRUG POTENTIATION; DRUG TREATMENT FAILURE; DRUG USE; HUMAN; MAJOR DEPRESSION; MONOTHERAPY; NONHUMAN; NUTRIENT SUPPLY; NUTRITIONAL DEFICIENCY; NUTRITIONAL HEALTH; PRESCRIPTION; PUERPERAL DEPRESSION; REVIEW; ADJUVANT CHEMOTHERAPY; NUTRITION; NUTRITIONAL STATUS;

AMINO ACIDS; ANTIDEPRESSIVE AGENTS; CHEMOTHERAPY, ADJUVANT; DEPRESSION; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; FOLIC ACID; HUMANS; NUTRITIONAL PHYSIOLOGICAL PHENOMENA; NUTRITIONAL STATUS; S-ADENOSYLMETHIONINE; TRYPTOPHAN;

EID: 65649090902     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1111/j.1753-4887.2009.00180.x     Document Type: Review

References (82)

1. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med. 2008;358:55-68.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th "Text Revision" ed. Arlington, VA: American Psychiatric Association; 2000.
3. World Health Organization. Mental and Neurological Disorders: "Depression". Fact Sheet Geneva: WHO; 2006.
4. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095-3105.
5. Alonso J, Angermeyer MC, Bernert S, et al. Prevalence of mental disorders in Europe: Results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl. 2004;420:21-27.
6. Kessler RC, Akiskal HS, Ames M, et al. Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am J Psychiatry. 2006; 163:1561-1568.
7. Parker G, Fletcher K. Treating depression with the evidencebased psychotherapies: A critique of the evidence. Acta Psychiatr Scand. 2007;115:352-359.
8. Lakhan SE, Vieira KF. Nutritional therapies for mental disorders. Nutr J. 2008;7:2.
9. Appleton KM, Peters TJ, Hayward RC, et al. Depressed mood and n-3 polyunsaturated fatty acid intake from fish: Nonlinear or confounded association? Soc Psychiatry Psychiatr Epidemiol. 2007;42:100-104.
10. Morris DW, Trivedi MH, Rush AJ. Folate and unipolar depression. J Altern Complement Med. 2008;14:277-285.
11. Parker G, Gibson N, Heruc G, Rees A, Hadzi-Pavlovic D. Omega-3 fatty acids and mood disorders. Am J Psychiatry. 2006;163:969-978.
12. Werneke U, Taylor T, Priebe S. Complementary medicines in psychiatry: Review of effectiveness and safety. Br J Psychiatry. 2006;188:109-121.
13. Appleton KM, Hayward RC, Gunnell D, et al. Effects of n-3 long-chain polyunsaturated fatty acids on depressed mood: Systematic review of published trials. Am J Clin Nutr. 2006; 84:1308-1316.
14. Sanchez-Villegas A, Henriquez P, Bes-Rastrollo M, Doreste J. Mediterranean diet and depression. Public Health Nutr. 2006;9:1104-1109.
15. Maes M, Smith R, Christophe A, Cosyns P, Desnyder R, Meltzer H. Fatty acid composition in major depression: Decreased omega 3 fractions in cholesteryl esters and increased C20 : 4omega6/C20 : 5omega3 ratio in cholesteryl esters and phospholipids. J Affect Disord. 1996;38:35-46.
16. Adams PB, Lawson S, Sanigorski A, Sinclair AJ. Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids. 1996;31: 157-161.
17. Dinan T, Siggins L, Scully P, O'Brien S, Ross P, Stanton C. Investigating the inflammatory phenotype of major depression: Focus on cytokines and polyunsaturated fatty acids. J Psychiatr Res. 2009;43:471-476.
18. Edwards R, Peet M, Shay J, Horrobin D. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J Affect Disord. 1998;48: 149-155. (Pubitemid 28244216)
19. Tassoni D, Kaur G, Weisinger RS, Sinclair AJ. The role of eicosanoids in the brain. Asia Pac J Clin Nutr. 2008;17:220-228.
20. Williams AL, Katz D, Ali A, Girard C, Goodman J, Bell I. Do essential fatty acids have a role in the treatment of depression? J Affect Disord. 2006;93:117-123.
21. Chalon S. Omega-3 fatty acids and monoamine neurotransmission. Prostaglandins Leukot Essent Fatty Acids. 2006;75: 259-269.
22. Hamazaki K, Itomura M, Huan M, et al. Effect of omega-3 fatty acid-containing phospholipids on blood catecholamine concentrations in healthy volunteers: A randomized, placebocontrolled, double-blind trial. Nutrition. 2005;21:705-710.
23. Chalon S, Delion-Vancassel S, Belzung C, et al. Dietary fish oilaffects monoaminergic neurotransmission and behavior in rats. J Nutr. 1998;128:2512-2519.
24. Delion S, Chalon S, Guilloteau D, Besnard JC, Durand G. alpha- Linolenic acid dietary deficiency alters age-related changes of dopaminergic and serotoninergic neurotransmission in the rat frontal cortex. J Neurochem. 1996;66:1582-1591.
25. Lin PY, Su KP. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry. 2007;68:1056-1061.
26. MontgomeryP,RichardsonAJ.Omega-3fatty acids for bipolar disorder. Cochrane Database Syst Rev. 2008;CD005169.
27. Rogers PJ, Appleton KM, Kessler D, et al. No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: A randomised controlled trial. Br J Nutr. 2008;99:421-431.
28. Marangell LB, Martinez JM, Zboyan HA, Kertz B, Kim HF, Puryear LJ. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry. 2003;160:996-998.
29. Grenyer BF, Crowe T,Meyer B. Fish oil supplementation in the treatment of major depression: A randomised double-blind placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1393-1396.
30. Garg ML,Wierzbicki AA, Thomson ABR, ClandininMT. Dietary cholesterol and/or n-3 fatty acid modulate [Delta]9- desaturase activity in rat liver microsomes. Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metab. 1988;962: 330-336.
31. Escudero A, Montilla JC, García JM, et al. Effect of dietary (n-9), (n-6) and (n-3) fatty acids on membrane lipid composition and morphology of rat erythrocytes. Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metab. 1998;1394: 65-73.
32. Stoll AL, Marangell L, Severus W. The effects of olive oil on omega-3 fatty acids and mood disorders: In reply. Arch Gen Psychiatry. 2000;57:715.
33. Nemets H, Nemets B, Apter A, Bracha Z, Belmaker RH. Omega-3 treatment of childhood depression: A controlled, double-blind pilot study. Am J Psychiatry. 2006;163:1098-1100.
34. Shanahan K, Zolkowski-Wynne J, Coury D, Collins E, O'Shea J. The children's depression rating scale for normal and depressed outpatients. Clin Pediatr. 1987;26:245-247.
35. Guy W, Bonato RE. CGI: Clinical Global Impressions. Manual for the ECDEU Assessment Battery, 2nd rev edn. Chevy Chase,MD: National Institute of Mental Health; 1970:12-1-12-16
36. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960:23:56-62.
37. Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression: Development of the 10-item Edinburgh Postnatal Depression Scale. Br J Psychiatry. 1987;150:782-786.
38. Su KP, Huang SY, Chiu TH. Omega-3 fatty acids for major depressive disorder during pregnancy: Results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2008;69:633-634.
39. Freeman MP, Hibbeln JR, Wisner KL, Brumbach BH, Watchman M, Gelenberg AJ. Randomized dose-ranging pilot trial of omega-3 fatty acids for postpartum depression. Acta Psychiatr Scand. 2006;113:31-35.
40. Browne JC, Scott KM, Silvers KM. Fish consumption in pregnancy and omega-3 status after birth are not associated with postnatal depression. J Affect Disord. 2006;90:131-139.
41. Jazayeri S, Tehrani-Doost T, Keshavarz A, et al. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. Aust N Z J Psychiatry. 2008;42:192-198.
42. Su KP, Huang SY, Chiu CC, Shen WW. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol. 2003; 13:267-271.
43. Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry. 2002;159:477-479.
44. Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry. 2002;59:913-919.
45. Taylor MJ, Carney SM, Goodwin GM, Geddes JR. Folate for depressive disorders: Systematic review and meta-analysis of randomized controlled trials. J Psychopharmacol. 2004;18: 251-256.
46. Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MW, Reynolds EH. Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry. 2000;69:228-232.
47. Folstein M, Liu T, Peter I, et al. The homocysteine hypothesis of depression. Am J Psychiatry. 2007;164:861-867.
48. Godfrey PS, Toone BK, Carney MW, et al. Enhancement of recovery from psychiatric illness by methylfolate. Lancet. 1990;336:392-395.
49. Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: A randomised, placebo controlled trial. J Affect Disord. 2000;60:121-130.
50. Papakostas GI, Petersen T, Lebowitz BD, et al. The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine. Int J Neuropsychopharmacol. 2005;8:523-528.
51. Roberts SH, Bedson E, Hughes D, et al. Folate augmentation of treatment - evaluation for depression (FolATED): Protocol of a randomised controlled trial. BMC Psychiatry. 2007;7:65.
52. Selhub J, Miller JW. The pathogenesis of homocysteinemia: Interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr. 1992;55:131-138.
53. Amsterdam JGC, Opperhuizen A. Nitric oxide and biopterin in depression and stress. Psychiatry Res. 1999;85:33-38.
54. Heseker H. Psychological disorders as early symptoms of a mild-to-moderate vitamin deficiency. Ann N Y Acad Sci. 1992;669:352-357.
55. Papakostas GI, Alpert JE, Fava M. S-adenosyl-methionine in depression: A comprehensive review of the literature. Curr Psychiatry Rep. 2003;5:460-466.
56. Williams AL, Girard C, Jui D, Sabina A, Katz DL. S-adenosylmethionine (SAMe) as treatment for depression: A systematic review. Clin Invest Med. 2005;28:132-139. (Pubitemid 40978708)
57. Agnoli A, Andreoli V, Casacchia M, Cerbo R. Effect of s-adenosyl-l-methionine (SAMe) upon depressive symptoms. J Psychiatr Res. 1976;13:43-54.
58. Alpert JE, Papakostas G, Mischoulon D, et al. S-adenosyl-Lmethionine (SAMe) as an adjunct for resistant major depressive disorder: An open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. J Clin Psychopharmacol. 2004;24:661-664.
59. Pancheri P, Scapicchio P, Chiaie RD. A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L- methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. Int J Neuropsychopharmacol. 2002;5:287-294.
60. Salmaggi P, Bressa GM, Nicchia G, Coniglio M, La Greca P, Le Grazie C. Double-blind, placebo-controlled study of S-adenosyl-L-methionine in depressed postmenopausal women. Psychother Psychosom. 1993;59:34-40.
61. Berlanga C, Ortega-Soto HA, Ontiveros M, Senties H. Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine. Psychiatry Res. 1992;44:257-262.
62. Rosenbaum JF, Fava M, Falk WE, et al. The antidepressant potential of oral S-adenosyl-l-methionine. Acta Psychiatr Scand. 1990;81:432-436.
63. Levine J, Barak Y, Gonzalves M, et al. Double-blind, controlled trial of inositol treatment of depression. Am J Psychiatry. 1995;152:792-794.
64. Levine J, Mishori A, Susnosky M, Martin M, Belmaker RH. Combination of inositol and serotonin reuptake inhibitors in the treatment of depression. Biol Psychiatry. 1999;45:270-273.
65. Nemets B,Mishory A, Levine J, Belmaker RH. Inositol addition does not improve depression in SSRI treatment failures. J Neural Transm. 1999; 106:795-798.
66. Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR D Project results: A comprehensive review of findings. Curr Psychiatry Rep. 2007;9:449-459.
67. Hood SD, Bell CJ, Nutt DJ. Acute tryptophan depletion. Part I: Rationale and methodology. Aust N Z J Psychiatry. 2005;39: 558-564.
68. Porter RJ, Mulder RT, Joyce PR, Luty SE. Tryptophan and tyrosine availability and response to antidepressant treatment in major depression. J Affect Disord. 2005;86:129-134.
69. Byerley WF, Judd LL, Reimherr FW, Grosser BI. 5-Hydroxytryptophan: A review of its antidepressant efficacy and adverse effects. J Clin Psychopharmacol. 1987;7:127-137.
70. Thomson J, Rankin H, Ashcroft GW, Yates CM, McQueen JK, Cummings SW. The treatment of depression in general practice: A comparison of L-tryptophan, amitriptyline, and a combination of L-tryptophan and amitriptyline with placebo. Psychol Med. 1982;12:741-751.
71. Glassman AH, Platman SR. Potentiation of a monoamine oxidase inhibitor by tryptophan. J Psychiatr Res. 1969;7:83-88.
72. Nardini M, De Stefano R, Iannuccelli M, Borghesi R, Battistini N. Treatment of depression with L-5- hydroxytryptophan combined with chlorimipramine, a double-blind study. Int J Clin Pharmacol Res. 1983;3:239-250.
73. Walinder J, Skott A, Carlsson A, Nagy A, Bjorn-Erik R. Potentiation of the antidepressant action of clomipramine by tryptophan. Arch Gen Psychiatry. 1976;33:1384-1389.
74. Coppen A, Shaw DM, Farrell JP. Potentiation of the antidepressive effect of a monoamine-oxidase inhibitor by tryptophan. Lancet. 1963;1:79-81.
75. Levitan RD, Shen JH, Jindal R, Driver HS, Kennedy SH, Shapiro CM. Preliminary randomized double-blind placebocontrolled trial of tryptophan combined with fluoxetine to treatmajor depressive disorder: Antidepressant and hypnotic effects. J Psychiatry Neurosci. 2000;25:337-346.
76. Shaw DM, Macsweeney DA, Hewland R, Johnson AL. Tricyclic antidepressants and tryptophan in unipolar depression. Psychol Med. 1975;5:276-278.
77. Ayuso Gutierrez JL, Lopez-Ibor Alino JJ, Montejo Iglesias L. [Tryptophan and amitriptyline in the treatment of depression (double blind study)]. Actas Luso Esp Neurol Psiquiatr Cienc Afines. 1973;1:471-476.
78. Praag HM. In search of the mode of action of antidepressants 5-HTP/tyrosine mixtures in depressions. Neuropharmacology. 1983;22:433-440.
79. Filippini G, Costa C, Bertazzo A. Recent advances in tryptophan research; tryptophan and serotonin pathways. Experiment Biol Med. 1996;398:762.
80. Wurtman R, Wurtman J. Carbohydrates and depression. Sci Am. 1989;260:68-75.
81. Groff J, Gropper S. Advanced Nutrition and Human Metabolism, 3rd edn. London: Wadsworth; 2000.
82. Guilarte TR. Effect of vitamin B-6 nutrition on the levels of dopamine, dopamine metabolites, dopa decarboxylase activity, tyrosine, and GABA in the developing rat corpus striatum. Neurochem Res. 1989;14:571-578.